Jefferies Conference

Michael J. Tokich, CFO and Treasurer

June 3, 2015

1

Forward Looking Statements

Except for historical information discussed, today’s presentation includes forward-looking

statements that involve risks and uncertainties. Investors are cautioned that such

statements are only current expectations, are not to be relied on, and that actual events or

results may differ materially. Some of the factors which could cause actual results to

materially differ from those anticipated by the forward-looking statements are set forth in the

Company’s SEC Filings on Forms 10-K, 10-Q and 8-K. Further, these forward-looking

statements speak only as of today’s date. We undertake no obligation to publicly release the

results of any revisions to the forward-looking statements made today to reflect other events

or circumstances or to reflect the occurrence of unanticipated events.

2

Company overview

3

Healthcare 75%

Life Sciences

14%

Isomedix 11%

STERIS Corporation Overview

• $1.9 billion in revenue

• 8,000 employees worldwide

– Direct sales and service

force of over 2,500

• A Global Leader in

infection prevention,

decontamination,

gastrointestinal and

surgical products

and services

• 78% of revenue in

United States

• 9 acquisitions in the last 3

years

• Infection

Prevention

• Surgical Solutions

• GI/Endoscopy

• Services

• Pharmaceutical

Manufacturing

• Research Labs

• Contract

Sterilization

4

Infection Prevention (40% of revenue)

Surgical Solutions (20% of revenue)

Service (40% of revenue)

Healthcare Segment Overview

Washers

Steam and

Gas Sterilizers

Cleaning

Chemistries

Service

Skin

Care

GI/Endoscopy

Solutions

Specialty

Services/Instrument Repair

Surgical Tables Integrated Operating Rooms

EBIT

55%

Revenue

75%

Lights

5

Healthcare Competitive Landscape

Surgical Solutions Infection Prevention Solutions

Ste

am

Ste

riliz

ers

Wa

she

rs/

Dis

infe

c.

Lo

w-t

em

p

Ste

riliz

ers

/

LC

PS

Lo

w-t

em

p

HL

D

GI

En

do

sco

py

SA

P

ICC

Lo

w-t

em

p

Ch

em

.

AIC

Su

rfa

ce

De

con

.

Ta

ble

s

Lig

hts

Arc

hite

ctu

ral

Su

pp

ort

Sta

inle

ss

Ste

el

OR

Inte

rgra

tion

STERIS

Getinge

3M

J&J

Belimed

Cantel Medical

Olympus

Cust. Ultrasonic

Boston Scientific

Cook Medical

Conmed

Ecolab

Medline

Dial

Clorox

GoJo

Trumpf

Stryker (Berchtold)

Skytron

Storz

(Estimate only, North America data) 6

Capital Equipment (35% of revenue)

Service (35% of revenue)

Consumables (30% of revenue)

Life Sciences Segment Overview

Washers Sterilizers VHP

Cleaning

Chemistries

Vaprox® Sterilant

25%

14%

EBIT Revenue

7

Isomedix Segment Overview

• 18 Isomedix facilities, 1 Biotest lab

• Contract sterilization, primarily of packaged products

and devices

• Primary Customers: Medical device manufacturers

• More than 80% of Customers on long-term contracts

Gamma Irradiation

Ethylene Oxide

24% 11%

EBIT Revenue

8

Our Long-Term Goals

• Revenue growth of mid- to high-single digits driven by:

– Market growth

– Success with new products

– Acquisitions

• Double-digit earnings per share growth driven by:

– Improved margins: volume growth, in-sourcing, and

new products

– Continued efficiencies and lean manufacturing

– R&D spending approximately 3% of total revenue

• Free cash flow of $125 million - $150 million annually

9

Recent Acquisitions

10

• Spectrum and TRE - October 2012

• Florida Surgical Repair – December 2013

• Life Systems, Inc. – February 2014

• Integrated Medical Systems – May 2014

11

Five businesses acquired:

Industry Consolidator – Instrument Repair

Other Acquisitions

– US Endoscopy – August 2012 (GI Consumable Business)

– VTS Medical – December 2012 (Integrated Operating Room Products)

– Eschmann – February 2014 (UK Surgical and Infection Control Business)

12

Celebrating 20 years of the Roth Net® retriever

Synergy Health Proposed Acquisition

• Global leader in outsourced sterilization

services for medical device

manufacturers, hospitals and other

industries.

Applied Sterilization Technologies (AST)

provider of outsourced sterilization to medical

device manufacturers

Hospital Sterilization Services (HSS)

provider of outsourced decontamination services

for reusable medical and surgical equipment

Healthcare Solutions (HCS)

provider of a range of products and services in

managing the environment in a healthcare setting

• FTC announced on May 29, 2015 that it

intends to challenge the merger

• STERIS and Synergy have reiterated their

commitment to the deal, and their intent to

contest the FTC challenge

• Long-stop date and financing agreement

to be pushed back to 12/31/15

13

26%

74%

Capital

Recurring

New STERIS

61% 28%

8% 3%

US

EMEA

APAC/LATAM

Canada

New STERIS

14

Questions?